Sign In
Buy RIGL
$41.30
-1.25 (-2.94%)
At Close: Jul 13, 2026
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
08:05am, Tuesday, 07'th Jul 2026
SOUTH SAN FRANCISCO, Calif., July 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. In
Rigel Appoints Board Member Alison L. Hannah, M.D.
08:05am, Wednesday, 01'st Jul 2026
Dr. Hannah has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021 She has resigned from Rigel's Board of Directors to join the company SOUTH SAN FR
A Look At The Transformation Around Rigel Pharmaceuticals
07:44am, Saturday, 20'th Jun 2026
Rigel Pharmaceuticals trades at an attractive valuation after a 35% pullback, with a market cap just over $600 million. RIGL's growth strategy pivots on the Veppanu licensing deal, supplementing stron
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
04:01pm, Tuesday, 16'th Jun 2026
SOUTH SAN FRANCISCO, Calif., June 16, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today anno
Rigel to Present at the Jefferies Global Healthcare Conference
08:05am, Wednesday, 27'th May 2026
SOUTH SAN FRANCISCO, Calif., May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announ
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
05:17pm, Thursday, 21'st May 2026
Oral presentation at ASCO Annual Meeting to feature final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO ® (pralsetinib) as first-line treatment in patients with RET fusion-positive N
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
08:05am, Thursday, 14'th May 2026
SOUTH SAN FRANCISCO, Calif., May 14, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today annou
Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript
11:10pm, Tuesday, 12'th May 2026
Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
02:38pm, Tuesday, 12'th May 2026
Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global licensing agreement with Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE
VEPPANU has a novel mechanism of action, is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript
07:51am, Wednesday, 06'th May 2026
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript
Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates
07:10pm, Tuesday, 05'th May 2026
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.63 per share a year ago.
Rigel Reports First Quarter 2026 Financial Results
04:01pm, Tuesday, 05'th May 2026
First quarter 2026 total revenues of $58.8 million, including net product sales of $54.9 million and contract revenues from collaborations of $3.9 million Generated $8.7 million of net income in the f
Rigel Pharmaceuticals (RIGL) to Report Q1 Results: Wall Street Expects Earnings Growth
11:06am, Tuesday, 28'th Apr 2026
Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
08:05am, Tuesday, 28'th Apr 2026
SOUTH SAN FRANCISCO, Calif., April 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2026 financial results after market close
